Literature DB >> 10675212

Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism.

B J Snow1, F J Vingerhoets, J W Langston, J W Tetrud, V Sossi, D B Calne.   

Abstract

OBJECTIVES: To examine the distribution of striatal dopaminergic function in humans with parkinsonism induced by 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP) to determine if there is a caudate-putamen gradient as is seen in idiopathic Parkinson's disease.
METHODS: We scanned nine humans exposed to MPTP with parkinsonism ranging from minimal to severe using [(18)F]fluorodopa (FD) and high resolution PET. The results were compared with those of 10 patients with Parkinson's disease and six normal subjects.
RESULTS: In the MPTP group there was an equal degree of reduction of dopaminergic function in the caudate and putamen. This was different from the greater putaminal than caudate loss in Parkinson's disease (p<0.001).
CONCLUSIONS: Parkinson's disease is not caused by transient exposure to MPTP.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10675212      PMCID: PMC1736814          DOI: 10.1136/jnnp.68.3.313

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  34 in total

1.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

Authors:  S J Kish; K Shannak; O Hornykiewicz
Journal:  N Engl J Med       Date:  1988-04-07       Impact factor: 91.245

2.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

3.  The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease.

Authors:  C Pifl; G Schingnitz; O Hornykiewicz
Journal:  Neurosci Lett       Date:  1988-10-05       Impact factor: 3.046

4.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

Authors:  J W Langston; P Ballard; J W Tetrud; I Irwin
Journal:  Science       Date:  1983-02-25       Impact factor: 47.728

5.  Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography.

Authors:  E S Garnett; C Nahmias; G Firnau
Journal:  Can J Neurol Sci       Date:  1984-02       Impact factor: 2.104

6.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  R S Burns; C C Chiueh; S P Markey; M H Ebert; D M Jacobowitz; I J Kopin
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

7.  Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease.

Authors:  D B Calne; J W Langston; W R Martin; A J Stoessl; T J Ruth; M J Adam; B D Pate; M Schulzer
Journal:  Nature       Date:  1985 Sep 19-25       Impact factor: 49.962

8.  Multiple system atrophy with autonomic failure: clinical, histological and neurochemical observations on four cases.

Authors:  E G Spokes; R Bannister; D R Oppenheimer
Journal:  J Neurol Sci       Date:  1979-09       Impact factor: 3.181

9.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.

Authors:  E Hirsch; A M Graybiel; Y A Agid
Journal:  Nature       Date:  1988-07-28       Impact factor: 49.962

10.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost?

Authors:  D C German; M Dubach; S Askari; S G Speciale; D M Bowden
Journal:  Neuroscience       Date:  1988-01       Impact factor: 3.590

View more
  16 in total

Review 1.  Glial cell response: A pathogenic factor in Parkinson's disease.

Authors:  Du Chu Wu; Kim Tieu; Oren Cohen; Dong-Kug Choi; Miquel Vila; Vernice Jackson-Lewis; Peter Teismann; Serge Przedborski
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

2.  Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism.

Authors:  Yilong Ma; Shichun Peng; Phoebe G Spetsieris; Vesna Sossi; David Eidelberg; Doris J Doudet
Journal:  J Cereb Blood Flow Metab       Date:  2011-11-30       Impact factor: 6.200

Review 3.  Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases.

Authors:  Lisa M Kosloski; Duy M Ha; Jessica A L Hutter; David K Stone; Michael R Pichler; Ashley D Reynolds; Howard E Gendelman; R Lee Mosley
Journal:  J Neurochem       Date:  2010-05-26       Impact factor: 5.372

4.  Early Postnatal Exposure to Paraquat and Maneb in Mice Increases Nigrostriatal Dopaminergic Susceptibility to a Re-challenge with the Same Pesticides at Adulthood: Implications for Parkinson's Disease.

Authors:  Dirleise Colle; Danúbia Bonfanti Santos; Aline Aita Naime; Cinara Ludvig Gonçalves; Heloisa Ghizoni; Mariana Appel Hort; Marcelo Farina
Journal:  Neurotox Res       Date:  2019-08-17       Impact factor: 3.911

Review 5.  Contributions of the striatum to learning, motivation, and performance: an associative account.

Authors:  Mimi Liljeholm; John P O'Doherty
Journal:  Trends Cogn Sci       Date:  2012-08-10       Impact factor: 20.229

6.  Expression of striatal preprotachykinin mRNA in symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys is related to parkinsonian motor signs.

Authors:  T V Wade; J S Schneider
Journal:  J Neurosci       Date:  2001-07-01       Impact factor: 6.167

7.  Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

Authors:  E Bezard; S Dovero; C Prunier; P Ravenscroft; S Chalon; D Guilloteau; A R Crossman; B Bioulac; J M Brotchie; C E Gross
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

Review 8.  Toxin-induced models of Parkinson's disease.

Authors:  Jordi Bové; Delphine Prou; Céline Perier; Serge Przedborski
Journal:  NeuroRx       Date:  2005-07

9.  Manganese-Induced Parkinsonism due to Ephedrone Abuse.

Authors:  Katrin Sikk; Sulev Haldre; Sten-Magnus Aquilonius; Pille Taba
Journal:  Parkinsons Dis       Date:  2011-02-17

Review 10.  Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease.

Authors:  Wassilios Meissner; Caroline Prunier; Denis Guilloteau; Sylvie Chalon; Christian E Gross; Erwan Bezard
Journal:  Mol Neurobiol       Date:  2003-12       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.